Silence is the only listed RNAi player in Europe and a pioneer in this technology. Through the efforts of our skilled scientists over the years we have established a robust platform that allows us to effectively trigger RNAi in specific cell types. Our inventions are protected by a broad intellectual property estate, which is a fundamental asset. Together with our progress, the fact that the field is generally maturing means that RNAi drugs are close to becoming a powerful genetic medicine modality at the disposal of doctors and patients.
Full Year Results 2016Download
Full Year Results 2016898KB Download
Half Year Results 2016614KB Download
Full Year Results 20151MB Download
Half Year Results 2015445KB Download
Full Year Results 2014494KB Download
Annual Report 2015978KB Download
Annual Report 20149MB Download
Annual Report 2013928KB Download
Annual Report 20121MB Download
Annual Report 20112MB Download
‘Therapeutic RNA delivery: into hepatocytes and beyond ’ AsiaTIDES Kyoto, 21-23 February 20171MB Download
'Hepatic gene disruption in vivo after liposomal delivery of Cas9 mRNA and chemically modified guide RNAs’ EuroTides Berlin, 14-16 November 20161MB Download
Atu027 Phase 2a Pancreatic Cancer Interim Analysis1MB Download
February 2015 Investor Presentation4MB Download
January 2015 Proactive Investors Presentation1MB Download
Our Corporate Governance framework is based on using the leadership provided by our Board to drive the effective execution of our strategy, ensuring that risk is appropriately mitigated and managed.
We have three Board Committees (Remuneration, Audit and Risk, and Nominations), focused on providing the required oversight to maintaining the highest Corporate Governance standards. Through these committees and regular interactions with the executive team, our Board applies internal financial controls and approves the Company’s policy and strategy.